R&D Solutions contracted backlog is IQVIA's contracted future work in its outsourced clinical-research and related R&D services business.
IQVIA reported $34.2B of contracted backlog at June 30, 2026, compared with a recast $34.0B at December 31, 2025.
Stock of contracted work, not current revenue
Backlog is accumulated contracted work, while R&D Solutions revenue is what was recognized in the period. The two should not be added or compared as if they use the same timing basis.
The more useful near-term bridge is next-12-month backlog conversion, because only part of total backlog is expected to become revenue within a year.
Primary sources: IQVIA Q2 2026 Form 10-Q and Q2 2026 earnings release filed with the SEC.
Continue Research
Continue from the concept into the Grizzly Bulls research surface that best matches the next question. These links are research continuations, not recommendations or required steps.
Compare stocks
Compare contracted clinical-research work and the pace at which issuers expect it to become revenue.
Explore more topics in the Financial Research Encyclopedia.